Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of modified-process tobramycin inhalation powder in cystic fibrosis with Pseudomonas aeruginosa infection
2008-002318-22Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tobramycin in cystic fibrosis (CF) and Pseudomonal infection (2 arms), sponsored by Novartis. Primary endpoint: Relative change in FEV1 percent predicted from baseline to day 29. Started Jan 2009; status: completed.
02
Drugs
tobramycin
03
Conditions
cystic fibrosis (CF)Pseudomonal infection
Beyond the preview
Go deeper on 2008-002318-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002318-22.